Market Size (2025)
$140.53M
Vertical: CNMBase Year: 2025
Market Size (2025)
$140.53M
Projected (2032)
$267.61M
CAGR (2022–2032)
9.7%
Key Players
9+
Market Overview
The Global Purpureocillium Lilacinum Market was valued at USD 140.53 Million in 2025, up from USD 106.21 Million in 2022. The market is projected to reach USD 267.61 Million by 2032, registering a CAGR of 9.62% over the forecast period 2026–2032. This represents an absolute increase of USD 127.08 Million between 2025 and 2032, which means the market is expected to almost double in value within seven years.
Purpureocillium lilacinum (formerly Paecilomyces lilacinus) is a soil-borne, egg-parasitic fungus commercialised as a biological nematicide. It is used mainly against root-knot (Meloidogyne spp.), cyst, lesion, reniform and burrowing nematodes in high-value horticulture and, increasingly, in broad-acre row crops. Demand is underpinned by the progressive withdrawal of older chemical nematicides, tighter maximum residue limit (MRL) requirements in export supply chains, the expansion of organic and residue-free production, and supportive regulatory pathways for low-risk microbial active substances. Two internationally registered strains, strain 251 and strain PL11, both approved in the European Union until 2037, anchor the regulated markets, while Brazil and India host a broad base of locally registered strains and products.
Key Findings
By formulation, Wettable Powder was the largest segment in 2025 with USD 70.26 Million (50.0% share), while Liquid is projected to be the fastest-growing segment at a CAGR of 11.07% during 2026–2032.
By crop type, Fruits & Vegetables was the largest segment in 2025 with USD 84.32 Million (60.0% share), while Cereals & Grains is projected to be the fastest-growing segment at a CAGR of 11.19% during 2026–2032.
By application method, Soil Treatment was the largest segment in 2025 with USD 105.40 Million (75.0% share), while Seed Treatment is projected to be the fastest-growing segment at a CAGR of 11.34% during 2026–2032.
By region, North America led the market in 2025 with USD 46.37 Million (33.0% share), while Asia Pacific is expected to be the fastest-growing region at a CAGR of 11.75%.
By country, the U.S. was the largest national market in 2025 at USD 37.10 Million, equal to 26.4% of global value, while India is projected to be the fastest-growing country at a CAGR of 13.10%.
Segmentation Summary
The market is analysed by formulation (Wettable Powder, Liquid and Granules), crop type (Fruits & Vegetables, Cereals & Grains and Others) and application method (Soil Treatment and Seed Treatment), across five regions and twenty countries and sub-regions. Wettable powders remain the dominant format because they are shelf-stable, inexpensive to manufacture from solid-state fermentation and widely registered. Liquid formulations, however, grow fastest (11.07% CAGR) as growers adopt drip-applied and tank-mix-compatible products. Fruits & vegetables account for 60.0% of 2025 value, reflecting the high economic damage of root-knot nematodes in tomato, cucurbits, peppers, banana and other horticultural crops. Cereals & grains show the strongest growth (11.19%), driven by seed treatment in soybean, maize and wheat systems. Soil treatment holds 75.0% of the market, while seed treatment expands at 11.34%.
Competitive Landscape Summary
The competitive landscape is fragmented. In regulated markets such as the European Union and the United States, competition centres on a small number of registered strains: strain 251, developed by Prophyta and owned by Bayer since 2009 and sold through BioAct products and the US MeloCon product line now marketed by Lallemand Plant Care as LALNIX ACT DC; and strain PL11, developed by LAM International and owned by Certis Biologicals, a subsidiary of Mitsui & Co. In Brazil, a large group of domestic biological companies, including Ballagro Agro Tecnologia, Vittia and Solubio, hold their own registrations for P. lilacinum products, while T. Stanes & Company is a long-established supplier in India. Companies compete on strain efficacy, spore concentration and shelf life, regulatory coverage, and access to distribution through alliances with large crop protection companies.
Challenges and Opportunities
The principal challenges are variable field efficacy compared with synthetic nematicides, slower onset of action, sensitivity of fungal spores to storage and soil conditions, and the cost and duration of microbial registration dossiers. Regulatory assessments also require attention to worker exposure because microorganisms are treated as potential sensitisers. Opportunities arise from the replacement of withdrawn chemistries such as fenamiphos and oxamyl in Europe, the rapid growth of on-seed biologicals in South American and North American row crops, combination products that pair P. lilacinum with other biocontrol agents, and the new Brazilian bioinputs legal framework (Law No. 15,070 of December 2024).
Future Outlook
Between 2025 and 2032 the market is expected to add USD 127.08 Million in value. Growth will shift gradually towards liquid and granular formats, seed treatment and cereals and grains, while fruits and vegetables and soil treatment continue to account for the majority of revenue. Asia Pacific, the Middle East & Africa and Latin America are all projected to grow faster than the global average, while North America and Europe remain the largest value pools. The table below summarises the leading and fastest-growing segment in each segmentation.
The Purpureocillium Lilacinum Market market is projected to grow at a CAGR of 9.7% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Purpureocillium lilacinum (Thom) Luangsa-ard, Houbraken, Hywel-Jones & Samson, formerly classified as Paecilomyces lilacinus, is a hyphomycete fungus of the family Ophiocordycipitaceae that occurs naturally in soils and the rhizosphere worldwide. It parasitises the eggs, juveniles and adult females of plant-parasitic nematodes. The fungus attaches to the nematode egg surface, penetrates the eggshell with the help of extracellular enzymes such as proteases and chitinases, and colonises the developing juvenile. It also produces secondary metabolites with nematicidal activity, and certain strains colonise the rhizosphere, which extends the period of protection around the root system.
For the purpose of this study, the Global Purpureocillium Lilacinum Market covers commercial plant protection products in which a strain of P. lilacinum is the active ingredient or one of the active ingredients, sold for the control of plant-parasitic nematodes in agriculture and horticulture. The market is valued at the manufacturer and supplier level in USD Million.
Included: registered or commercially sold wettable powder, liquid (suspension concentrate, oil dispersion, dispersible concentrate and similar liquid formats) and granular products containing P. lilacinum; single-strain products and combination products in which P. lilacinum is a declared active ingredient; products applied as soil treatment (in-furrow, drench, drip or chemigation, transplant and nursery media) or as seed treatment.
Excluded: other nematophagous fungi and bacteria sold without P. lilacinum (for example Pochonia chlamydosporia, Trichoderma spp. or Bacillus spp. products), botanical and chemical nematicides, P. lilacinum used in non-agricultural applications such as industrial enzymes or research reagents, and on-farm multiplied inoculum that is not sold as a commercial product.
Scope of the Study
The study quantifies the Global Purpureocillium Lilacinum Market in value terms for historic years 2022, 2023 and 2024, the base year 2025 and the forecast years 2026 to 2032. All values are presented in USD Million, and growth rates are expressed as CAGR for 2026–2032. The scope covers the following segmentations, regions and countries:
By Formulation: Wettable Powder, Liquid, Granules
By Crop Type: Fruits & Vegetables, Cereals & Grains, Others
By Application Method: Soil Treatment, Seed Treatment
North America: U.S., Canada, Mexico
Europe: Germany, U.K., France, Italy, Spain, Rest of Europe
Asia Pacific: China, India, Japan, Rest of Asia Pacific
Latin America: Brazil, Argentina, Rest of Latin America
Middle East & Africa: UAE, Saudi Arabia, South Africa, Rest of MEA
Research Objectives
To estimate the size of the Global Purpureocillium Lilacinum Market for 2022–2025 and forecast it to 2032 in USD Million.
To segment and quantify the market by formulation, crop type and application method, and identify the largest and fastest-growing segments.
To analyse regional and country-level demand for P. lilacinum products across North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.
To assess the drivers, restraints, opportunities and challenges that affect the adoption of P. lilacinum as a substitute for, or complement to, chemical nematicides.
To review the regulatory status of P. lilacinum strains and products in major jurisdictions, including the European Union, the United States, India and Brazil.
To evaluate the value chain from strain selection and fermentation through formulation, distribution and on-farm use.
To profile the competitive environment, including key suppliers, their positioning and strategic developments since 2022.
To identify investment and product development opportunities in liquid formulations, seed treatment and combination products.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured, multi-stage research process. It begins with defining the market and its segmentation, followed by extensive secondary research to build a database of registered P. lilacinum products, active suppliers, crop areas affected by nematodes and regulatory status by country. Primary research with participants across the value chain is then used to validate assumptions on pricing, formulation mix, application practices and adoption rates. Market size is estimated using both top-down and bottom-up approaches and triangulated to arrive at final values, after which forecasts are developed using a factor-based model. All outputs pass through internal quality checks for consistency across segments, regions and years.
Secondary Research
Secondary research covered publicly available and paid sources relevant to biological crop protection and nematode management, including:
Regulatory and government bodies: the European Commission and EU Pesticides Database, the European Food Safety Authority (EFSA), national authorities such as ANSES (France) and Ctgb (Netherlands), the US Environmental Protection Agency (EPA) and California Department of Pesticide Regulation, India's Central Insecticides Board & Registration Committee (CIB&RC), Brazil's Ministry of Agriculture and Livestock (MAPA) and its AGROFIT database, and agricultural ministries in other countries.
Research institutions: national agricultural research systems such as the Indian Council of Agricultural Research (ICAR) institutes, the USDA Agricultural Research Service, Embrapa and university nematology departments, together with publications from the Food and Agriculture Organization (FAO).
Industry associations: biological crop protection associations such as the Biological Products Industry Alliance (BPIA), the International Biocontrol Manufacturers Association (IBMA) and CropLife, along with Brazilian bioinput industry bodies.
Company sources: annual reports, investor presentations, product labels, technical data sheets and press releases of manufacturers and distributors.
Trade journals and databases: crop protection and horticulture trade press, peer-reviewed journals in nematology and biological control, agricultural statistics from FAOSTAT and national statistical offices, and paid company and trade databases.
Primary Research
Primary research was conducted through in-depth telephone and online interviews with participants on both the supply side and the demand side of the market. The interviews were used to verify secondary findings, fill information gaps and obtain qualitative insight into market trends.
Supply side: executives, product managers and technical managers at biological crop protection manufacturers, strain developers and contract fermentation companies; regulatory affairs specialists; and distributors and agro-dealers.
Demand side: commercial growers of vegetables, fruits, banana, soybean, sugarcane and other crops affected by nematodes; agronomists and crop consultants; seed companies offering biological seed treatments; and researchers in public nematology programmes.
Objectives: to validate product pricing and formulation mix, application rates and methods, adoption levels by crop and region, competitive positioning, and expectations for regulatory and demand developments over the forecast period.
Market Size Estimation
The top-down approach starts from the wider biological nematicide and biocontrol markets in each region and applies the share attributable to P. lilacinum products, derived from product registration counts, supplier revenue information and expert input. The bottom-up approach builds the market from the demand side by estimating the treated area for each crop type and application method, multiplying it by application rates and average selling prices, and aggregating the results by country and region. Supplier revenue estimates for P. lilacinum products are used as an additional cross-check.
The results of the two approaches are reconciled through data triangulation. Where the estimates diverge, the underlying assumptions are re-examined against primary interview findings, and the final market values are fixed only when the supply-side and demand-side views are consistent within an acceptable range.
Forecasting Methodology
Forecasts for 2026–2032 are developed from the 2025 base-year estimates using a factor-based model. The factors considered include:
Regulatory changes affecting chemical nematicides and the registration of microbial active substances.
Growth in harvested area and production of nematode-susceptible crops, particularly fruits, vegetables, soybean and other row crops.
Adoption trends for biologicals, organic farming and residue-management programmes in export-oriented agriculture.
Technology developments in strain selection, fermentation, formulation and seed treatment.
Macroeconomic conditions, agricultural commodity prices and farm incomes, and currency movements.
Each factor is weighted by region and segment based on its expected impact, and the resulting growth rates are reviewed with industry experts before being finalised.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024
Base year: 2025
Forecast period: 2026–2032
Currency: USD Million
Growth metric: CAGR for 2026–2032
Assumptions and Limitations
Market values are expressed in nominal US dollars. Local-currency revenues are converted at average annual exchange rates, so currency movements may affect reported values for individual countries.
The regulatory framework in each country is assumed to evolve along currently announced lines, without unexpected bans or approvals of competing nematicides.
Products that contain P. lilacinum together with other microorganisms are included at their full value where P. lilacinum is a declared active ingredient.
Many suppliers are privately held and do not disclose product-level revenue, so supplier-side estimates rely on registration data, pricing and expert interviews.
Informal, unregistered and on-farm produced inoculum is excluded, which may understate actual product usage in some developing markets.
The forecast does not account for extreme events such as major trade disruptions, pandemics or severe climate events beyond normal year-to-year variation.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Purpureocillium Lilacinum Market is fragmented, with a mix of multinational crop protection companies, specialist biological companies and regional manufacturers. Its structure differs markedly between regions. In the European Union and the United States, where registration of a microbial active substance requires extensive data, the market is concentrated around two strains with international approvals: strain 251, developed by the German company Prophyta and owned by Bayer since 2009, and strain PL11, developed by LAM International and owned by Certis Biologicals, a wholly owned subsidiary of Mitsui & Co. Several companies market products based on these strains through licensing and distribution agreements.
In Brazil and India, registration of locally isolated strains has created a much larger number of suppliers. Brazil in particular has a crowded field of domestic registrants, including Ballagro Agro Tecnologia, Vittia, Solubio, Companhia Nitro Química Brasileira, Solatus, B Plant, Innova, Massen and JCO Fertilizantes, many of which market several brands built on the same strain. Competition is based on strain efficacy data, spore concentration and product quality, shelf life, breadth of registrations and crops on label, and access to distribution. Alliances with major crop protection companies, such as FMC's agreement with Ballagro, are increasingly important for scaling up sales.
Key Player Positioning
Leaders: Bayer AG and Certis Biologicals (Mitsui & Co.) are the market leaders by virtue of owning the two strains with EU-level approval and long-standing US registrations, combined with global distribution networks. Bayer markets strain 251 under the BioAct brand alongside its chemical nematicide Velum in integrated nematode programmes, and its Crop Science division reported sales of EUR 21.622 billion in fiscal year 2025. Certis Biologicals holds the low-risk EU approval for PL11, launched NemaClean in Europe in 2025 and sells PL11 in the United States and, through Mitsui & Co. (Brasil), in Brazil. Its parent, Mitsui & Co., reported revenue of JPY 13,995.2 billion for the fiscal year ended March 2026.
Challengers: Lallemand Plant Care, Ballagro Agro Tecnologia, T. Stanes & Company and Vittia are strong challengers. Lallemand, a privately held Canadian company, has built a biocontrol portfolio through acquisitions and now markets strain 251 in the United States as LALNIX ACT DC. Ballagro is a leading Brazilian specialist in fungal biological nematicides, with reported annual revenue of about BRL 200 million, and has a licensing and distribution agreement with FMC. T. Stanes, founded in 1861, is one of India's longest-established biological input companies and sells the CIB&RC-registered Bio-Nematon. Vittia, listed on the Brazilian stock exchange B3, reported net revenue of BRL 820 million in 2025, of which BRL 275.3 million came from biological and natural solutions.
Niche players: Solubio, Dudutech IPM (Bioline AgroSciences group) and BioBee serve specific regions or crop segments. Solubio markets P. lilacinum under several brands in Brazil, Dudutech supplies East and Southern African horticulture from its Kenyan production base, and BioBee offers its BioPae product as part of an integrated pest management portfolio. A long tail of smaller Brazilian and Indian producers also competes in local markets.
Competitor Dashboard
The dashboard below rates each profiled company on four parameters relevant to its position in the market.
Threat of New Entrants: Medium
Regulatory data requirements and strain safety assessment create high barriers in the European Union and the United States.
Barriers are lower in Brazil and India, where many local companies have registered P. lilacinum products based on domestic isolates.
Fermentation technology is widely available, but scale, quality control and distribution access favour established suppliers.
Bargaining Power of Suppliers: Low
Fermentation substrates, carriers and packaging materials are commodity inputs available from many sources.
Strain ownership sits mainly with the product companies themselves, which limits dependence on outside suppliers.
Contract fermentation capacity is increasing, which gives product companies more sourcing options.
Bargaining Power of Buyers: Medium
Large distributors, cooperatives and multinational partners negotiate volume-based pricing.
Growers can choose among several biological and chemical alternatives, which limits pricing power for suppliers.
Fragmented smallholder demand in Asia and Africa reduces the bargaining power of individual buyers in those regions.
Threat of Substitutes: High
Newer chemical nematicides offer faster and more predictable control in many crops.
Other biologicals, including Bacillus-based seed treatments, Pochonia chlamydosporia, Trichoderma spp. and botanical products, compete for the same applications.
Cultural practices such as crop rotation, resistant varieties, soil solarisation and grafting reduce the need for nematicide applications.
Intensity of Competitive Rivalry: Medium
The market is fragmented, with a few international strain owners and many regional suppliers.
Competition in Brazil is intense, with many registered P. lilacinum products and multiple brands built on the same strains.
Competition is based on efficacy data, product quality, regulatory coverage and technical support rather than price alone.
Threat of New Entrants: Medium; High regulatory barriers in the EU and US; lower barriers in Brazil and India.
Bargaining Power of Suppliers: Low; Commodity inputs; strain ownership held by product companies.
Bargaining Power of Buyers: Medium; Large distributors and partners negotiate; many alternatives available.
Threat of Substitutes: High; Chemical nematicides, other biologicals and cultural practices.
Competitive Rivalry: Medium; Fragmented market; intense competition in Brazil.
Market estimates by geography (2032)
InsightNorth America leads with $80.91M by 2032, while Asia Pacific is projected to grow fastest at a 12.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $36.32M | $54.19M | $80.91M | 8.3% | 30% |
| Europe | $26.76M | $39.29M | $58.31M | 8.1% | 22% |
| Asia Pacific | $17.52M | $32.08M | $55.57M | 12.2% | 21% |
| Latin America | $21.35M | $36.50M | $60.64M | 11.0% | 23% |
| Middle East & Africa | $4.25M | $7.09M | $12.18M | 11.1% | 5% |
| Total | $106.21M | $169.16M | $267.61M | 9.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$267.61M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Wettable Powder | $122.71M | 8.3% | 46% |
| Liquid | $88.42M | 11.4% | 33% |
| Granules | $56.48M | 10.6% | 21% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Purpureocillium Lilacinum Market covering market dynamics, competitive landscape, and strategic outlook.
The Purpureocillium Lilacinum Market market is projected to reach $267.61M by 2032, growing at 9.7% CAGR. The Wettable Powder segment holds the largest share.
The Global Purpureocillium Lilacinum Market is shaped by the interaction of regulatory, agronomic, technological and economic forces. Plant-parasitic nematodes are among the most damaging soil-borne pests in agriculture, and the main chemical tools used against them have come under sustained regulatory pressure. This has opened room for biological alternatives such as P. lilacinum, whose adoption is supported by low-risk regulatory pathways and the residue requirements of retailers and importers. At the same time, the market is held back by more variable field performance than synthetic chemistry, the logistical demands of living products and the cost of registration.
The growth factor analysis below summarises the main macro and micro factors and their expected impact over three periods of the forecast. Impact scores are analyst assessments on a scale of 1 to 10, where a higher score indicates a stronger influence on the market. They are based on secondary research and discussions with industry participants.
Phase-Out of Chemical Nematicides
The withdrawal of older, highly toxic nematicides is the most important driver of demand for P. lilacinum. In the European Union, the approval of fenamiphos was not renewed under Commission Implementing Regulation (EU) 2020/1246, and oxamyl was not renewed under Implementing Regulation (EU) 2023/741, with the use of existing stocks ending on 1 November 2023. Soil fumigants and organophosphate and carbamate nematicides face restrictions in many other jurisdictions as well, and methyl bromide has been phased out for most agricultural uses under the Montreal Protocol. Growers of tomatoes, cucurbits, peppers, carrots and potatoes, which are highly susceptible to root-knot and cyst nematodes, have therefore lost a significant part of their toolbox. Newer chemical nematicides are available, but resistance management, residue limits and the desire to reduce chemical loads in the soil are pushing growers to integrate biological products into their programmes. P. lilacinum, with its well-documented egg-parasitic activity and long history of commercial use, is one of the most established biological options. It is often used at planting and through drip irrigation to suppress nematode populations before they reach damaging levels.
Supportive Regulatory Pathways for Low-Risk Microbials
Regulators increasingly provide favourable routes for microbial plant protection products. In the European Union, P. lilacinum strain PL11 was approved as a low-risk active substance under Commission Implementing Regulation (EU) 2022/4, with approval running until January 2037. Strain 251 was renewed under Implementing Regulation (EU) 2022/19 until February 2037. Low-risk status brings a longer approval period and faster product authorisation. In March 2025, the Netherlands granted the first EU product authorisation for NemaClean, a PL11-based product, as a low-risk product. In the United States, the EPA registers microbial pesticides through its Biopesticides and Pollution Prevention Division, and P. lilacinum strain 251 has been exempt from the requirement of a tolerance since 2005. These pathways allow residue-free positioning, short pre-harvest intervals and compatibility with organic production. They make P. lilacinum attractive to growers who supply retailers with strict residue specifications, and they lower the commercial risk for companies investing in new registrations.
Expansion of High-Value Horticulture and Residue-Sensitive Supply Chains
Fruits & vegetables account for 60.0% of the Global Purpureocillium Lilacinum Market in 2025, valued at USD 84.32 Million. Protected cultivation of tomatoes, cucumbers and peppers in Southern Europe, North Africa, the Middle East, China and Mexico is expanding, and greenhouse and tunnel soils are especially prone to root-knot nematode build-up because of continuous cropping. At the same time, major retailers and importers impose maximum residue limits that are often stricter than legal requirements and restrict the number of residues allowed per product. Exporters of berries, bananas, avocados and vegetables therefore favour inputs that leave no residues of concern. P. lilacinum products fit this need, and they are also eligible for organic production in many markets, where demand for certified produce continues to grow. These factors combine to create steady demand for biological nematicides across the horticultural value chain.
Rapid Growth of Biologicals in South American Row Crops
Brazil has become one of the most dynamic markets for biological nematicides. Soybean, maize, cotton and sugarcane fields are affected by lesion nematodes (Pratylenchus brachyurus), soybean cyst nematode (Heterodera glycines) and root-knot nematodes, and growers have adopted biological nematicides on a large scale through seed and in-furrow treatments. Brazil's Ministry of Agriculture and Livestock recorded a record 162 bioinput registrations in 2025, and many P. lilacinum products are registered by domestic companies. Law No. 15,070 of 23 December 2024 established a dedicated legal framework for bioinputs, covering their production, registration and on-farm use. This scale of adoption in row crops is the main reason why seed treatment (11.34% CAGR) and cereals & grains (11.19% CAGR) are the fastest-growing segments in their respective segmentations.
Liquid and Seed-Applied Formulations
Liquid formulations are the fastest-growing formulation segment at a CAGR of 11.07%. Liquid concentrates are easier to apply through drip irrigation, compatible with seed treatment equipment and convenient for tank mixing. The launch of MeloCon LC in the United States in January 2022 and its successor LALNIX ACT DC show how suppliers are shifting strain 251 into liquid formats. Further investment in oil dispersions, stabilised conidia and seed-coating technologies can extend shelf life and open new crops.
Combination and Integrated Nematode Management Products
Combining P. lilacinum with other biocontrol agents, such as Pochonia chlamydosporia or Bacillus strains, can widen the spectrum of activity and improve consistency. Brazilian companies already market such combinations, for example Ballagro's Nemat Stellus, which pairs P. lilacinum with P. chlamydosporia. Integrated programmes that pair biologicals with reduced rates of chemical nematicides are also gaining acceptance among large growers and distributors.
Untapped Markets in Asia Pacific and the Middle East & Africa
Asia Pacific (11.75% CAGR) and the Middle East & Africa (11.55% CAGR) are projected to be the fastest-growing regions. India, China and the Gulf states have large areas of vegetables and fruits under intensive cultivation and protected agriculture, rising awareness of soil health, and government programmes to reduce chemical pesticide use. Wider product registration, local production and farmer training can unlock substantial demand in these regions.
Variable Field Efficacy and Slower Action
The performance of P. lilacinum depends on soil temperature, moisture, organic matter, pH and the existing microbial community. The fungus must establish in the rhizosphere and reach eggs to be effective, so it acts more slowly than contact chemical nematicides and usually provides suppression rather than near-complete control. Under heavy nematode pressure, growers often see less consistent results than with synthetic products, and some reviews, including FAO publications on biological control of nematodes, note that high application rates may be needed. This variability limits use as a stand-alone solution and makes adoption dependent on technical support and integrated programmes.
Shelf Life, Handling and Registration Costs
As a living product, P. lilacinum requires controlled storage and handling to maintain spore viability, which adds cost to the distribution chain, particularly in hot climates. Microbial registration requires strain identification, toxicological and ecotoxicological data, and assessment of possible human health effects. Some clinical isolates of the species are opportunistic human pathogens, so regulators examine strain safety closely, and EU approval conditions require personal protective equipment because microorganisms are treated as potential sensitisers. These requirements raise registration costs and lengthen time to market, which restricts the number of strains approved in regulated markets.
Competition from Alternative Nematicides
P. lilacinum competes with newer chemical nematicides that offer more predictable control, as well as with other biologicals such as Bacillus-based products, Pochonia chlamydosporia, Trichoderma spp. and botanical extracts. Several major crop protection companies market their own biological nematicide seed treatments built on bacterial strains, which compete directly with fungal products in row crops.
Consolidation and Partnerships in Biologicals
Large crop protection companies are building biological portfolios through acquisitions, licensing and distribution agreements, while specialist biological companies are themselves being acquired or attracting private equity investment. Examples include Lallemand Plant Care taking over distribution of the MeloCon strain 251 product in the United States, now marketed as LALNIX ACT DC, FMC's licensing and distribution agreement with Ballagro in Brazil in September 2024, and Eurazeo's majority investment in Bioline AgroSciences, the parent of Dudutech, in 2025.
Shift to Proprietary, Well-Characterised Strains
Suppliers are investing in proprietary strains with documented safety and efficacy, supported by genome-based identification. This trend favours companies with strong research and regulatory capabilities and builds barriers to entry in regulated markets. In Brazil, companies are accelerating strain discovery through partnerships such as the one between Ballagro and Symbiomics announced in December 2025.
Quality Control and Product Consistency
Quality is a key challenge, particularly in markets with many small producers. Variation in spore counts, contamination and viability can damage grower confidence in biological nematicides as a category. Regulators and industry bodies are tightening quality standards, and Brazil's new bioinputs law is expected to formalise requirements for both commercial and on-farm production.
Climate Variability and Soil Health Focus
Warmer soils and longer growing seasons can increase the number of nematode generations per season and expand the range of some species. At the same time, the growing focus on soil health and regenerative agriculture encourages growers to use biological inputs that support the soil microbiome. Both trends are expected to support steady long-term demand for P. lilacinum products.
The value chain of the P. lilacinum market comprises four main stages, from strain development and raw material supply to end use on the farm.
Raw materials and inputs: The key input is a characterised, proprietary or licensed strain of P. lilacinum maintained in culture collections. Fermentation inputs include cereal grains such as rice, agricultural by-products, sugars, nitrogen sources and growth media, together with carriers (clays, talc, kaolin), surfactants, oils and packaging materials. Strain development and regulatory data generation are high-value activities at this stage.
Manufacturing: Conidia are produced mainly by solid-state fermentation, although liquid fermentation is also used. The spores are harvested, dried and formulated into wettable powders, water-dispersible granules, granules or liquid concentrates, followed by quality control of spore count, viability, purity and contamination. Some companies manufacture in-house, while others use contract fermentation or toll manufacturing, as in FMC's agreement with Ballagro in Brazil.
Distribution and channels: Products reach growers through national distributors, agro-dealers and cooperatives, through partnerships with multinational crop protection companies, and through direct sales to large farms and greenhouse operators. Seed companies and seed treatment service providers form an important channel for seed-applied products. Cold-chain or temperature-controlled storage helps maintain shelf life.
End users: End users include commercial growers of vegetables and fruits in open fields and protected cultivation, banana and plantation crops, row-crop farmers using seed and in-furrow treatments, organic producers, nurseries and turf and ornamental managers. Agronomists and crop advisers play an important role in product selection.
European Union: Plant protection products are regulated under Regulation (EC) No 1107/2009. P. lilacinum strain 251 was first approved through Commission Directive 2008/44/EC and renewed under Commission Implementing Regulation (EU) 2022/19 until 28 February 2037. Strain PL11 was approved as a low-risk active substance under Commission Implementing Regulation (EU) 2022/4 until 24 January 2037. Products are authorised at member-state level through the zonal system, as shown by the NemaClean authorisation in the Netherlands in 2025 and the ANSES evaluation in France. Data requirements for microorganisms were updated in 2022 to reflect their biological properties.
United Kingdom: Following its exit from the EU, Great Britain applies a retained version of Regulation (EC) No 1107/2009, administered by the Health and Safety Executive (HSE).
United States: Pesticides are registered by the EPA under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), with residue tolerances and exemptions set under the Federal Food, Drug, and Cosmetic Act. Strain 251 was first registered in 2005 (MeloCon WG), and products containing strain PL11 were registered in 2021. States such as California have additional registration requirements through the Department of Pesticide Regulation, and organic use is governed by the USDA National Organic Program.
India: Biopesticides are registered by the Central Insecticides Board & Registration Committee (CIB&RC) under the Insecticides Act, 1968. P. lilacinus formulations, including T. Stanes' 1.15% WP, are listed among registered bio-insecticides with label claims for root-knot nematode control. The Insecticides (Prohibition) Order, 2023 further restricted several chemical pesticides.
Brazil: Pesticides and biological control agents are registered under Law No. 14,785 of 2023, which replaced the earlier pesticides law, with MAPA as the registering authority. Law No. 15,070 of 2024 created a specific framework for bioinputs, including on-farm production. Numerous P. lilacinum products are registered in the AGROFIT system.
Other regions: In China, pesticides are registered through the Institute for the Control of Agrochemicals, Ministry of Agriculture and Rural Affairs (ICAMA). In South Africa, agricultural remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). In Kenya, the Pest Control Products Board (PCPB) regulates pest control products.
The table below lists key launches, regulatory approvals, acquisitions and partnerships involving companies active in the market since 2022.
January 2022: Certis Biologicals (LAM International); Regulatory approval; EU approved P. lilacinum strain PL11 as a low-risk active substance under Implementing Regulation (EU) 2022/4, valid until January 2037.
January 2022: Bayer AG; Regulatory renewal; EU renewed the approval of P. lilacinum strain 251 under Implementing Regulation (EU) 2022/19, valid until February 2037.
January 2022: Lallemand Plant Care / Bayer AG; Acquisition; Lallemand acquired Bayer's worldwide CONTANS biofungicide business, expanding its biocontrol portfolio.
January 2022: Certis Biologicals; Product launch; Launched MeloCon LC, a liquid formulation of strain 251, in the United States; the product is OMRI-listed.
June 2023: Certis Biologicals; Registration; MeloCon LC approved by the California Department of Pesticide Regulation.
March 2024: Certis Biologicals; Acquisition; Acquired the Howler and Theia biofungicides from AgBiome, broadening its biological portfolio.
August 2024: Ballagro Agro Tecnologia; Acquisition; Acquired a 70% stake in Sementes Piraí.
September 2024: Ballagro Agro Tecnologia / FMC; Partnership; FMC agreed to license, distribute and source fungal biological solutions manufactured by Ballagro in Brazil.
January 2025: Bayer AG / Ecospray; Partnership; Exclusive distribution agreement for Velsinum, a garlic-based biological nematicide, with sales planned from 2026.
February 2025: Lallemand Plant Care; Product launch; Introduced LALNIX ACT DC, the strain 251 nematicide formerly sold as MeloCon, after taking over its distribution in the United States.
March 2025: Certis Biologicals; Registration; Obtained the first EU product authorisation for NemaClean (PL11) in the Netherlands as a low-risk product for fruiting vegetables.
March 2025: Bioline AgroSciences (Dudutech IPM); Acquisition; Eurazeo's Planetary Boundaries Fund took a majority stake in Bioline AgroSciences, the parent company of Dudutech.
May 2025: Mitsui AgriScience International (Certis); Regulatory approval; ANSES issued a favourable evaluation of NemaClean for four greenhouse vegetable uses in France.
December 2025: Ballagro Agro Tecnologia / Symbiomics; Partnership; Entered a research partnership to accelerate the discovery of new biological strains.
Political:
Government strategies such as the EU Farm to Fork Strategy, which set a target of reducing the use and risk of chemical pesticides by 50% by 2030, and Japan's MIDORI Strategy for Sustainable Food Systems encourage biological alternatives.
National programmes promoting organic and natural farming in India and bioinput policies in Brazil support adoption.
Economic:
Higher prices and margins for residue-free and organic produce justify investment in biological crop protection.
Commodity price volatility and high input costs can delay adoption among price-sensitive growers.
Currency fluctuations affect the value of sales in emerging markets when expressed in US dollars.
Social:
Consumer concern about pesticide residues and the environmental impact of agriculture drives retailer requirements for cleaner inputs.
Growing awareness of soil health among farmers supports the use of microbial products.
Technological:
Improvements in solid-state fermentation, spore stabilisation and liquid formulation are extending shelf life and ease of use.
Genomic tools are improving strain selection, identification and regulatory characterisation.
Seed treatment and drip application technologies broaden the ways the product can be delivered.
Environmental:
P. lilacinum is naturally occurring and has a favourable environmental profile compared with soil fumigants and organophosphate nematicides.
Climate change may increase nematode pressure and alter the regions where nematodes cause economic damage.
Legal:
Low-risk active substance status in the EU and tolerance exemptions in the US reduce residue-related legal barriers.
Strict data requirements, strain safety assessment and worker protection conditions increase the legal burden of registration.
Intellectual property protection for proprietary strains and formulations shapes competitive positions.
Profiles of 109 companies operating in the Purpureocillium Lilacinum Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
4 interactive charts drawn from the Purpureocillium Lilacinum Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Purpureocillium Lilacinum Market By Application Method
Global Purpureocillium Lilacinum Market By Crop Type
Global Purpureocillium Lilacinum Market By Formulation
Global Purpureocillium Lilacinum Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)